Table 1 |
||||
|
Participant characteristics at baseline assessment |
||||
|
Normal Weight (n = 16) |
Obese (n = 16) |
|||
|
+IR |
-IR |
+IR |
-IR |
|
|
|
||||
|
N (females) |
8 (5) |
8 (5) |
8 (6) |
8 (6) |
|
Anti-TNFα agent (Infliximab/Etanercept/Adalimumab) |
5/3/0 |
4/3/1 |
6/2/0 |
5/3/0 |
|
Smokers (current; ex) |
3 (1; 2) |
4 (1; 3) |
3 (2; 1) |
4 (2; 2) |
|
Age (years) |
60.8 |
62.2 |
58.6 |
60.8 |
|
(6.9) |
(7.8) |
(6.7) |
(8.0) |
|
|
Height (cm) |
165.9 |
167 |
165.4 |
165.2 |
|
(10.6) |
(12.2) |
(11.9) |
(9.4) |
|
|
Weight (kg) |
60.3 |
61.6 |
88.9 |
89.8 |
|
(6.4) |
(7.2) |
(10.1) |
(9.6) |
|
|
BMI (kg/m2) |
21.8 |
22.1 |
32.3 |
32.8 |
|
(2.4) |
(2.2) |
(3.0) |
(3.1) |
|
|
HOMA |
2.9 |
2.2* |
3.1 |
2.1# |
|
(0.7) |
(0.4) |
(0.5) |
(0.8) |
|
|
QUICKI |
0.29 |
0.36* |
0.30 |
0.37# |
|
(0.02) |
(0.03) |
(0.03) |
(0.01) |
|
|
HAQ |
1.6 |
1.8 |
1.7 |
2.0 |
|
(0.3) |
(0.2) |
(0.4) |
(0.5) |
|
|
DAS |
5.7 |
5.9 |
6.2 |
6.1 |
|
(0.7) |
(0.5) |
(1.0) |
(0.6) |
|
|
ESR (mm/h) |
31 |
38 |
35 |
43 |
|
(7.5) |
(10) |
(9.5) |
(12.5) |
|
|
CRP (mg/L) |
29 |
32.5 |
31.4 |
34.2 |
|
(6.4) |
(8.2) |
(8.8) |
(7.4) |
|
|
Disease Duration |
9.1 |
8.6 |
8 |
10.2 |
|
(years) |
(2.5) |
(2.3) |
(3.6) |
(4.7) |
|
|
||||
|
* Significantly different compared to N+IR (P < 0.05). # Significantly different compared to O+IR (P < 0.05). BMI, body mass index; CRP, C-reactive protein; DAS, disease activity score 28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; +IR, with insulin resistance; -IR, without insulin resistance; HOMA, Homeostasis Model Assessment Of Insulin Resistance; QUICKI, Quantitative Insulin Sensitivity Check Index |
||||
|
Stavropoulos-Kalinoglou et al. Arthritis Research & Therapy 2012 14:R160 doi:10.1186/ar3900 |
||||
